Petros Nikolinakos

University Cancer and Blood Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index6.9kcitations91works11.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(19), Lung Cancer Treatments and Mutations(17), Colorectal Cancer Treatments and Studies(16), Cancer Immunotherapy and Biomarkers(13), Renal cell carcinoma treatment(13)

Publications89 total

Abstract P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
Clinical Cancer Research·2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
ESMO Open·2025· 37 citedOpen Access
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).
Journal of Clinical Oncology·2024· 4 cited
Abstract PO1-04-02: ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan
Cancer Research·2024
CTC-Race: Single-Cell Motility Assay of Circulating Tumor Cells from Metastatic Lung Cancer Patients
ACS Nano·2024· 18 citedOpen Access
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
The Breast·2023· 38 citedOpen Access
Thromboinflammation prevention in COVID-19 hospitalised patients: A retrospective study
Atherosclerosis·2023
Data from A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
2023Open Access
Supplementary Data from A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
2023· 1 citedOpen Access
Data from A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
2023Open Access
Supplementary Data from A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
2023Open Access
Supplementary Figure from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023Open Access
Data from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023· 1 citedOpen Access
Supplementary Figure from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023Open Access
Supplementary Table from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023Open Access
Supplementary Table from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023Open Access
Supplementary Figure from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023· 1 citedOpen Access
Supplementary Figure from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023Open Access
Data from Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2023Open Access
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
The Oncologist·2022· 23 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

John V. Heymach(8), Jamie Hodgson(8), Mary G. Egan(6), Guy Jérusalem(5), Wujun Zhao(5), Yang Liu(5), Leidong Mao(5), Changchun Deng(4), Rui Cheng(4), Ralph V. Boccia(3), Anja von Heydebreck(3), Kevin M. Chin(3), Scott Kopetz(3), David Waterhouse(3), Jason C. Chandler(3), Maen Hussein(3), Ben Creelan(3), David R. Spigel(3), Donald Richards(3), Lyudmila Bazhenova(3)